What's Happening?
Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker, has announced the enrollment of the first patient in its first-in-human study for Pulsatile Intravascular Lithotripsy (PIVL) therapy. This study, known as the POWER
CAD I, aims to evaluate the feasibility of the Pulse IVL System in treating patients with moderate to severely calcified coronary arterial disease. The study will involve up to 15 subjects across four facilities in Australia and New Zealand, with primary endpoints assessed at 30 days. The first procedure was conducted by Dr. Jithendra Somaratne at Auckland City Hospital. The Pulse IVL System is designed to offer easy delivery and efficient treatment of complex calcified lesions, marking a significant milestone in expanding the application of this technology to coronary disease.
Why It's Important?
The development of the Pulse IVL System represents a significant advancement in the treatment of calcified coronary artery disease, a condition that can complicate stent placement and lead to poor patient outcomes. By utilizing a unique hydraulic mechanism, the system aims to improve the deliverability and efficiency of intravascular lithotripsy, potentially offering a new treatment option for patients with this challenging condition. The success of this study could pave the way for broader adoption of this technology, improving patient outcomes and expanding the market for intravascular lithotripsy devices. This development is particularly important as it addresses a critical need in cardiovascular care, potentially reducing the risk of complications and improving the quality of life for patients.
What's Next?
Following the initial enrollment, the POWER CAD I study will continue to enroll additional patients, with results expected to inform future clinical trials and regulatory submissions. If successful, the study could lead to the commercialization of the Pulse IVL System, providing a new tool for cardiologists in the treatment of calcified coronary artery disease. Stakeholders, including healthcare providers and patients, will be closely monitoring the outcomes of this study, as it could significantly impact treatment protocols and patient care standards. Additionally, Stryker's acquisition of AVS positions the company to leverage this innovative technology, potentially expanding its market share in the cardiovascular device sector.
